Type of security: Stock
Sector: Health Care
Industry: Major Pharmaceuticals
The data is delayed by 15 minutes.
ABT is in the long-term up 112% in 4 years.
Description: Abbott Laboratories manufactures and sells health care products worldwide. Its Established Pharmaceutical Products segment offers branded generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome, intrahepatic cholestasis or depressive symptoms, gynecological disorders, dyslipidemia, hypertension, hypothyroidism, pain, fever, and inflammation; and regulates physiological rhythm of the colon, as well as provides hormone replacement therapy and anti-infective and influenza vaccines. The company?s Diagnostic Products segment provides diagnostic systems and tests, such as immunoassay and clinical chemistry systems; assays for screening and diagnosis for drugs of abuse, cancer, therapeutic drug monitoring, fertility, and physiological and infectious diseases; hematology systems and reagents; genomic-based tests; informatics and automation solutions; and diagnostic systems and tests for blood analysis, as well as instruments that automate the extraction, purification,
See how to gain 20% in 14 sec with TrendsInvesting
|Shares Outstanding||EPS||0.94||EPS Growth - 4 Quarters||1349.62%||EPS Growth - Q/Q||238.84%|
|EPS Growth - Y/Y||-44.39%||Sales Growth - 4 Quarters||-18.92%||Sales Growth - Q/Q||-7.43%||P/E||51.29|
|P/E To EPS Growth||P/S||P/BV||Price/Cash Per Share|
|Price/Free Cash Flow||ROA||9.75%||ROE||19.21%||ROI||12.44%|
|Current Ratio||2.17||Quick Ratio||1.89||Long Term Debt/Equity||0.55||Debt Ratio||0.42|
|Gross Margin||55.74%||Operating Margin||13.95%||Net Profit Margin||20.6%||Dividend Payout Ratio||-32.44%|
|Cash From Financing Activities||-550 M||Cash From Investing Activities||-205 M||Cash From Operating Activities||2 M||Gross Profit||2.95 B|
|Net Profit||784 M||Operating Profit||729 M||Total Assets||43.1 B||Total Current Assets||19.99 B|
|Total Current Liabilities||9.21 B||Total Debt||8.46 B||Total Liabilities||21.22 B||Total Revenue||5.17 B|
|High 52 week||79.73||Low 52 week||53.74||Last close||75.97||Last change||-0.82%|
|RSI||36.28||Average true range||1.51||Beta||0.56||Volume||3.81 M|
|Simple moving average 20 days||-1.58%||Simple moving average 50 days||-2.29%||Simple moving average 200 days||14.05%|
|Performance Week||-0.63%||Performance Month||4.24%||Performance Quart||1.37%||Performance Half||29.53%|
|Performance Year||36.11%||Performance Year-to-date||22.22%||Volatility daily||1.12%||Volatility weekly||2.5%|
|Volatility monthly||5.12%||Volatility yearly||17.75%||Relative Volume||228.71%||Average Volume||5.53 M|
|New High||New Low|
2019-09-17 08:38:12 | Abbott Partners With Sanofi to Upgrade Diabetes Management
2019-09-16 17:50:09 | Abbott ABT Dips More Than Broader Markets: What You Should Know
2019-09-16 08:29:12 | Abbott's ABT FreeStyle Libre Gains Canadian Reimbursement
2019-09-15 08:00:46 | Startup uses remittances to remove 'time and distance' from health care
2019-09-12 12:56:00 | Abbott Declares 383rd Consecutive Quarterly Dividend
2019-09-11 14:03:45 | Pharma Stock Calls Could Double Fast
2019-09-11 09:30:01 | Abbott Sees Hammer Chart Pattern: Time to Buy?
2019-09-10 17:45:09 | Abbott ABT Stock Sinks As Market Gains: What You Should Know
2019-09-10 05:54:00 | Abbott Labs Falls 3%
2019-09-09 11:27:03 | Abbott ABT Launches Pivotal Trial TRILUMINATE in the US
2019-09-04 06:58:55 | Does Abbott Laboratories's NYSE:ABT CEO Salary Compare Well With Others?
2019-09-03 19:12:50 | Medtronic, Other Medtech Providers Could Face Additional Tariffs
2019-09-03 14:34:38 | How one company is working to improve equality in the STEM world
2019-09-03 08:11:12 | Here's Why You Should Hold on to Thermo Fisher TMO for Now
2019-09-03 07:02:11 | 5 Cancer-Fighting Stocks to Add to Your Portfolio
2019-08-31 07:29:00 | Is Dexcom a Buy?
2019-08-29 22:56:35 | Top 5 Recession Stocks
2019-08-28 17:50:09 | Abbott ABT Outpaces Stock Market Gains: What You Should Know
2019-08-27 08:56:12 | Here's Why You Should Add Abbott ABT to Your Portfolio
2019-08-27 08:54:12 | Abbott's ABT TRACK-TBI Study Reveals Encouraging Results
2019-08-26 09:30:01 | Has Abbott Laboratories ABT Outpaced Other Medical Stocks This Year?
2019-08-26 09:00:01 | Abbott ABT Upgraded to Buy: What Does It Mean for the Stock?
2019-08-25 07:30:00 | 3 Fantastic Stocks for Low-Risk Investors
2019-08-23 13:45:35 | Strategic Value Investing: Estimates of Cash Flows
2019-08-23 11:30:00 | Abbott Labs Falls 3%
2019-08-22 17:45:09 | Abbott ABT Dips More Than Broader Markets: What You Should Know
2019-08-22 11:45:03 | Abbott's Libre Adoption a Positive, Rhythm Management a Woe
2019-08-21 14:04:06 | Top Stock Reports for Home Depot, Abbott & Bristol-Myers
2019-08-21 11:05:03 | Tandem Diabetes Rides on t:slim X2 Uptake, Product Pipeline
2019-08-21 11:00:03 | FDA OKs Medtronic's Evolut TAVR New Indication for Low Risk
2019-08-21 10:05:00 | 3 Top Diabetes Stocks to Watch in August
2019-08-20 08:14:12 | Here's Why You Should Hold Onto IDEXX IDXX Stock for Now
2019-08-20 06:26:07 | Have Insiders Been Selling Abbott Laboratories NYSE:ABT Shares?
2019-08-16 09:30:01 | Abbott ABT Down 4.4% Since Last Earnings Report: Can It Rebound?
2019-08-14 10:42:00 | Abbott Labs Falls 3%
2019-08-13 07:05:11 | 5 Stocks Trading Near 52-Week High With More Room to Run
2019-08-09 20:15:03 | Abbott Laboratories ABT Executive Vice President & CFO Brian B Yoor Sold $3. ...
2019-08-06 09:30:01 | Is Abbott Laboratories ABT Outperforming Other Medical Stocks This Year?